Navigation Links
Prometheus Strengthens Intellectual Property Portfolio with Newly Issued Patents for Thiopurine Metabolite Testing
Date:10/30/2008

SAN DIEGO, Oct. 30 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostics company, announced that the U.S. Patent and Trademark Office (USPTO) has issued two separate patents covering the technology for PROMETHEUS(R) Thiopurine Metabolites, a diagnostic test that enables physicians to optimize ongoing dosing of thiopurines to reach and maintain desired therapeutic levels. The USPTO has approved the issuance of the claims in U.S. Patent Nos. 7,425,546 and 7,429,570, both entitled, "Methods of optimizing drug therapeutic efficacy for treatment of immune- mediated gastrointestinal disorders."

"We are pleased that the USPTO has acknowledged the validity of these patents and approved their issuance," said William Franzblau, Vice President of Legal Affairs for Prometheus. "This is another example of our ongoing commitment to growing our substantial intellectual property portfolio, which we believe is a key competitive advantage. In addition, we will continue to protect and vigorously enforce our proprietary rights, if necessary."

PROMETHEUS(R) Thiopurine Metabolites helps keep patients' drug metabolite levels within an optimal therapeutic range, thereby increasing the probability of a positive response and potentially reducing the need for other medications. Thiopurine metabolites testing helps identify some of the reasons for treatment failure and monitor for potential toxicity before it occurs.

Combined, Prometheus' thiopurine management diagnostic tests - PROMETHEUS(R) TPMT Genetics and PROMETHEUS(R) TPMT Enzyme for individualizing dosing before therapy, and PROMETHEUS(R) Thiopurine Metabolites for optimizing dosing during therapy - provide information that helps physicians better manage therapeutic treatment, achieve better clinical outcomes and lower the potential for toxicity.

About Thiopurines

Thiopurines are a class of drugs that include azathioprine and mercaptopurine. These drugs are indicated as an adjunct for the prevention of rejection in renal homotransplantations, as well as for the management of active rheumatoid arthritis to reduce signs and symptoms. Although not indicated for inflammatory bowel disease, thiopurines are sometimes prescribed by physicians for such use. Their effectiveness and side effects can vary due to each person's ability to process or metabolize thiopurines. Most people have no problem metabolizing thiopurines, however, less than one percent of patients have almost no ability to metabolize these drugs. Failure to metabolize thiopurines can result in myelosuppression and hepatotoxicity, which can lead to death.

About Prometheus

Prometheus Laboratories Inc. is a specialty pharmaceutical and diagnostics company committed to developing and commercializing novel pharmaceutical and diagnostic products to help physicians individualize patient care. Prometheus is currently focused on the detection, diagnosis and treatment of gastrointestinal diseases and disorders in the United States. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary, high-value diagnostic testing services. By integrating pharmaceutical products and diagnostic testing services, Prometheus believes it can address the full continuum of care, thereby providing physicians with a comprehensive solution to treat chronic diseases. Prometheus' corporate offices are located in San Diego, California.


'/>"/>
SOURCE Prometheus Laboratories Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Prometheus Licenses COLAL-PRED(R) From Alizyme
2. Medpace Strengthens Presence in Central Europe
3. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
4. Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board
5. DuPont Joint Venture with Chinese Biotech Firm Strengthens Gene Discovery Research Efforts
6. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
7. Anavex strengthens Board of Directors
8. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
9. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
10. JobLoft.com Strengthens Local Market Candidate Reach Through RegionalHelpWanted.com Acquisition
11. BioSpace.com Strengthens Local Market Candidate Reach Through RegionalHelpWanted.com Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , Jan. 17, 2017 Roka Bioscience, Inc. (NASDAQ: ... advanced testing solutions for the detection of foodborne pathogens today announced ... Ms. Duseau succeeds Paul Thomas , the Company,s President and ... the Company,s Board of Directors.  The changes are effective today. ... Directors, effective today. ...
(Date:1/17/2017)... 17, 2017 Research and Markets has ... Diagnostics - Technologies, Markets and Companies" to their offering. ... ... remarkably during the past few years. More than 1,000 companies ... and 342 of these are profiled in the report along ...
(Date:1/17/2017)... , ... January 17, 2017 , ... Pono Ola ... peaceful and healthy lifestyle, announced today the official launch of its much-anticipated Pono Board: ... mind. , In development for over a year, the patented Pono Board ...
(Date:1/17/2017)... , Jan. 17, 2017  Protagonist Therapeutics, Inc. ... it has initiated a global Phase 2b induction ... peptide that targets alpha4beta7 integrin. The aim of ... to evaluate the safety/tolerability and efficacy of PTG-100 ... moderate to severe active disease. ...
Breaking Biology Technology:
(Date:1/12/2017)... 2017  Trovagene, Inc. (NASDAQ: TROV ), ... announced that it has signed agreements with seven strategic ... Middle East for commercialization of ... first wave of international distribution agreements for Trovagene,s CLIA ... The initial partners will introduce Trovagene,s liquid ...
(Date:1/6/2017)... , Jan. 6, 2017  Privately-held CalciMedica, ... studies in healthy volunteers of a novel calcium ... treat acute pancreatitis. Acute pancreatitis, ... a mild disorder, but can be very serious.  In ... and sepsis, where extended hospital stays, time in ...
(Date:1/3/2017)... 3, 2017 Onitor, provider of digital health ... Track, an innovative biometric data-driven program designed to aid ... at the 2017 Consumer Electronics Show (CES) in ... the U.S., the World Health Organization (WHO), have identified ... adults who are overweight or obese. WHO also states ...
Breaking Biology News(10 mins):